Drug Safety-related Labeling Changes (SrLC) Database
ANDA | Abbreviated New Drug Application |
BLA | Biologics License Application |
CDER | Center for Drug Evaluation and Research |
MG | Medication Guide |
NDA | New Drug Application |
PCI | Patient Counseling Information |
PI | Patient Information |
PLR | Physician Labeling Rule |
PLLR | Pregnancy and Lactation Labeling Rule |
Italics | For the most part, italics indicate an FDA comment such as:
Additions and/or revisions underlined These italics usually appear at the beginning of the section. In some cases, italics may be an inherent part of the label, and will most often appear in the body of the section. |
Underlines | Any text that is underlined indicates text that has been added or revised. There are exceptions where underlining occurs in a section subtitle or heading. This is the case when there is just one word underlined in the body of the text. |
Sections
BW | Box Warning |
WP | Warnings and Precautions all in one section (PLR-format) Warnings as one section (pre-PLR format) Precautions as one section (pre-PLR format) |
AR | Adverse Reactions (in pre-PLR format, this may be a subheading under precautions). |
DI | Drug Interactions (in pre-PLR format, this may be a subheading under precautions). |
USP | Use in Specific Populations (Inclusive on one or more of the following: Pregnancy; Lactation (PLLR- format); Nursing Mothers (pre-PLLR format); Females and Males of Reproductive Potential (PLLR format only); Pediatric Use, Geriatric Use, Renal Impairment, Hepatic Impairment, Sex, Race (these last six may be a subheading of precautions if label in pre-PLLR format. |
PCI/PI/MG | Patient Counseling Information (PLR format only) - summarizes the information that a health care provider should convey to a patient (or caregiver when applicable) when a counseling discussion is taking place (e.g., a physician prescribing a drug during an office visit, a nurse providing discharge instructions at a hospital, or a pharmacist conveying information at a pharmacy). Patient Information - FDA approved patient labeling. Medication Guide - paper handouts that come with many prescription medicines. The guides address issues that are specific to particular drugs and drug classes, and they contain FDA-approved information that can help patients avoid serious adverse events. |
Only NDAs and CDER regulated BLAs are included in this database. ANDAs are not included.
Applications that remain active, even if the product has been discontinued, undergo safety-related labeling changes.
VICTOZA (NDA-022341)
(LIRAGLUTIDE RECOMBINANT)
Safety-related Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)
07/05/2023 (SUPPL-39)
5 Warnings and Precautions
5.5 Acute Kidney InjurySection title revised
Newly added information:
VICTOZA is contraindicated in patients who have had a serious hypersensitivity reaction to liraglutide or any of the excipients in VICTOZA [see Contraindications (4)].6 Adverse Reactions
Additions and revisions underlined:
The following serious adverse reactions are described below or elsewhere in the prescribing information:
Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]
Pancreatitis [see Warnings and Precautions (5.2)]
Hypoglycemia [see Warnings and Precautions (5.4)]
Renal ImpairmentAcute Kidney Injury [see Warnings and Precautions (5.5)]
. . .
Extensive changes; please refer to label
7 Drug Interactions
7.1 Effects of Delayed Gastric Emptying on Oral MedicationsSection title revised
Newly added information:
VICTOZA stimulates insulin release in the presence of elevated blood glucose concentrations. Patients receiving VICTOZA in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.
8 Use in Specific Populations
8.5 Geriatric UseNewly added information:
No overall differences in safety or effectiveness for VICTOZA have been observed between patients 65 years of age and older and younger patients.
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
PATIENT COUNSELING INFORMATIONAdditions and revisions underlined:
Inform patients that liraglutide causes benign and malignant thyroid C-cell tumors in mice and rats and that the human relevance of this finding has not been determined.is unknown.
. . .
06/10/2022 (SUPPL-38)
5 Warnings and Precautions
5.7 Acute Gallbaldder DiseaseAdditions and/or revisions underlined:
Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In the LEADER trial [see Clinical Studies (14.3)], 3.1% of VICTOZA-treated patients versus 1.9% of placebo-treated patients reported an acute event of gallbladder disease, such as cholelithiasis or cholecystitis [see Adverse Reactions (6.1)]. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
6 Adverse Reactions
Addition of the following to the bulleted line listing:
Acute Gallbladder Disease [see Warnings and Precautions (5.7)]
6.1 Clinical Trials Experience
Additions and/or revisions underlined:
…
Cholelithiasis and cholecystitis
In glycemic control trials of VICTOZA, the incidence of cholelithiasis was 0.3% in both VICTOZA-treated and placebo-treated patients. The incidence of cholecystitis was 0.2% in both VICTOZA-treated and placebo-treated patients.
In the LEADER trial [see Clinical Studies (14.3)], the incidence of cholelithiasis was 1.5% (3.9 cases per 1000 patient years of observation) in VICTOZA-treated and 1.1% (2.8 cases per 1000 patient years of observation) in placebo-treated patients, both on a background of standard of care. The incidence of acute cholecystitis was 1.1% (2.9 cases per 1000 patient years of observation) in VICTOZA-treated and 0.7% (1.9 cases per 1000 patient years of observation) in placebo-treated patients. The majority of events required hospitalization or cholecystectomy.
…
6.3 Postmarketing Experience
Additions and/or revisions underlined:
The following additional adverse reactions have been reported during post-approval use of VICTOZA. Because these events are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Medullary thyroid carcinoma
Dehydration resulting from nausea, vomiting and diarrhea.
Increased serum creatinine, acute renal failure or worsening of chronic renal failure, sometimes requiring hemodialysis.
Angioedema and anaphylactic reactions.
Allergic reactions: rash and pruritus
Skin and subcutaneous tissue disorder: cutaneous amyloidosis
Acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death
Hepatobiliary disorders: hyperbilirubinemia, elevations of liver enzymes, cholestasis, hepatitis, cholecystitis, cholelithiasis requiring cholecystectomy
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
MEDICATION GUIDEAdditions and/or revisions underlined:
…
Who should not use VICTOZA?
Do not use VICTOZA if:
you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
you have had a serious allergic reaction to liraglutide or any of the ingredients in VICTOZA. See the end of this Medication Guide for a complete list of ingredients in VICTOZA. Symptoms of a serious allergic reaction include:
swelling of your face, lips, tongue or throat
problems breathing or swallowing
severe rash or itching
fainting or feeling dizzy
very rapid heartbeat
…
How should I use VICTOZA?
…
- Change (rotate) your injection site within the area you choose with each injection to reduce your risk of getting lumps under the skin (cutaneous amyloidosis). Do not use the same site for each injection.
…
What are the possible side effects of VICTOZA?
VICTOZA may cause serious side effects, including:
…
gallbladder problems. Gallbladder problems have happened in some people who take VICTOZA. Tell your healthcare provider right away if you get symptoms of gallbladder problems which may include:
pain in your upper stomach (abdomen)
yellowing of skin or eyes (jaundice)
fever
clay-colored stools
…
What are the ingredients in VICTOZA? Active ingredient: liraglutide
Inactive ingredients: disodium phosphate dihydrate, propylene glycol, phenol and water for injection, hydrochloric acid or sodium hydroxide may be added to adjust pH11/20/2020 (SUPPL-36)
5 Warnings and Precautions
5.4 HypoglycemiaAdditions underlined
Adult patients receiving VICTOZA in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with VICTOZA regardless of insulin and/or metformin use. [see Adverse Reactions (6.1), Drug Interactions (7.2)].
The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin. Inform patients using these concomitant medications and pediatric patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
8 Use in Specific Populations
8.4 Pediatric UseAdditions underlined
… The risk of hypoglycemia was higher with VICTOZA in pediatric patients regardless of insulin and/or metformin use.
…
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
MEDICATION GUIDEAdditions underlined
…
What is VICTOZA?
…
VICTOZA is not for use in people with type 1 diabetes. It should not be used with It should not be used with other medicines that contain liraglutide.
…
How should I use VICTOZA?
…
If you take too much VICTOZA, call your healthcare provider right away. Taking too much VICTOZA may cause severe nausea, severe vomiting, and low blood sugar (hypoglycemia).
…
Additions underlined…
Hypoglycemia
Inform patients that hypoglycemia has been reported when VICTOZA is used with insulin secretagogues or insulin and may occur in pediatric patients regardless of concomitant antidiabetic treatment. Educate patients or caregivers on the signs and symptoms of hypoglycemia.
…
06/17/2019 (SUPPL-31)
5 Warnings and Precautions
5.4 Use with Medications Known to Cause Hypoglycemia(Newly added Subsection)
In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with VICTOZA regardless of concomitant antidiabetic therapies.
6 Adverse Reactions
6.1 Clinical Trials Experience(Additions and/or revisions underlined)
Common Adverse Reactions
The safety of Victoza in subjects with type 2 diabetes was evaluated in 5 glycemic control, placebo-controlled trials in adults and one trial of 52 weeks duration in pediatric patients 10 years of age and older. The data in Table 1 reflect exposure of 1673 adult patients to VICTOZA and a mean duration of exposure to VICTOZA of 37.3 weeks. The mean age of adult patients was 58 years, 4% were 75 years or older and 54% were male. The population was 79% White, 6% Black or African American, 13% Asian; 4% were of Hispanic or Latino ethnicity. At baseline the population had diabetes for an average of 9.1 years and a mean HbA1c of 8.4%. Baseline estimated renal function was normal or mildly impaired in 88.1% and moderately impaired in 11.9% of the pooled population.
Table 1 shows common adverse reactions in adults, excluding hypoglycemia, associated with the use of VICTOZA. These adverse reactions occurred more commonly on VICTOZA than on placebo and occurred in at least 5% of patients treated with VICTOZA. Overall, the type, and severity of adverse reactions in adolescents and children aged 10 years and above were comparable to that observed in the adult population.
Hypoglycemia
In 5 adult glycemic control, placebo-controlled clinical trials of at least 26 weeks duration, hypoglycemia requiring the assistance of another person for treatment occurred in 8 VICTOZA-treated patients (7.5 events per 1000 patient-years). Of these 8 VICTOZA-treated patients, 7 patients were concomitantly using a sulfonylurea.
Table 2 Adult Incidence (%) and Rate (episodes/patient year) of Hypoglycemia in 26-Week Combination Therapy Placebo- controlled Trials
In a 26-week pediatric placebo-controlled clinical trial with a 26-week open-label extension, 21.2% of VICTOZA treated patients (mean age 14.6 years) with type 2 diabetes, had hypoglycemia with a blood glucose <54 mg/dL with or without symptoms (335 events per 1000 patient years). No severe hypoglycemic episodes occurred in the VICTOZA treatment group (severe hypoglycemia was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions).
(Additions and/or revisions underlined)
Of the 11 VICTOZA-treated patients who developed anti-liraglutide antibodies, none were observed to develop neutralizing antibodies to liraglutide, and 5 patients (0.4%) developed cross-reacting antibodies against native GLP-1.
In a clinical trial with pediatric patients 10 to 17 years, anti-liraglutide antibodies were detected in 1 (1.5%) VICTOZA treated patient at week 26 and 5 (8.5%) VICTOZA treated patients at week 53. None of the 5 had antibodies cross reactive to native GLP-1 or had neutralizing antibodies.
7 Drug Interactions
7.2 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin(Newly added Subsection)
When initiating VICTOZA, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
8 Use in Specific Populations
8.1 Pregnancy(Additions and/or revisions underlined)
Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia related morbidity.
(Additions and/or revisions underlined)
The safety and effectiveness of VICTOZA as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus have been established in pediatric patients 10 years of age and older. Use of VICTOZA for this indication is supported by a 26-week placebo-controlled clinical trial and a 26-week open-label extension in 134 pediatric patients 10 to 17 years of age with type 2 diabetes, a pediatric pharmacokinetic study, and studies in adults with type 2 diabetes mellitus. The risk of hypoglycemia was higher with VICTOZA in pediatric patients regardless of concomitant antidiabetic therapies.
The safety and effectiveness of VICTOZA have not been established in pediatric patients less than 10 years of age.
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
MEDICATION GUIDE(Additions and/or revisions underlined)
What is VICTOZA?
VICTOZA is an injectable prescription medicine used:
along with diet and exercise to lower blood sugar (glucose) in adults and children who are 10 years of age and older with type 2 diabetes mellitus.
to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes mellitus with known heart disease.
VICTOZA is not for use in people with type 1 diabetes or people with diabetic ketoacidosis. It is not known if VICTOZA can be used with mealtime insulin.
It is not known if VICTOZA is safe and effective to lower blood sugar (glucose) in children under 10 years of age.
What are the possible side effects of VICTOZA? VICTOZA may cause serious side effects, including:
low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use VICTOZA with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. In children who are 10 years of age and older, the risk for low blood sugar may be higher with VICTOZA regardless of use with another medicine that can also lower blood sugar.
08/25/2017 (SUPPL-27)
4 Contraindications
(additions underlined)
Medullary Thyroid Carcinoma
VICTOZA is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Hypersensitivity
VICTOZA is contraindicated in patients with a prior serious hypersensitivity reaction to VICTOZA or to any of the product components. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with VICTOZA.
5 Warnings and Precautions
5.2 Pancreatitis(additions underlined)
Based on spontaneous postmarketing reports, acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with VICTOZA. After initiation of VICTOZA, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, VICTOZA should promptly be discontinued and appropriate management should be initiated. If pancreatitis is confirmed, VICTOZA should not be restarted.
In glycemic control trials of VICTOZA, there have been 13 cases of pancreatitis among VICTOZA-treated patients and 1 case in a comparator (glimepiride) treated patient (2.7 vs. 0.5 cases per 1000 patient-years). Nine of the 13 cases with VICTOZA were reported as acute pancreatitis and four were reported as chronic pancreatitis. In one case in a VICTOZA-treated patient, pancreatitis, with necrosis, was observed and led to death; however clinical causality could not be established. Some patients had other risk factors for pancreatitis, such as a history of cholelithiasis or alcohol abuse.
VICTOZA has been studied in a limited number of patients with a history of pancreatitis. It is unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis on VICTOZA.
(additions underlined)
There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) in patients treated with VICTOZA. If a hypersensitivity reaction occurs, discontinue VICTOZA; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous hypersensitivity reaction to VICTOZA.
Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to reactions with VICTOZA.
(new subsection added)
In the LEADER trial, 3.1% of Victoza-treated patients versus 1.9% of placebo- treated patients reported an acute event of gallbladder disease, such as cholelithiasis or cholecystitis. The majority of events required hospitalization or cholecystectomy. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
6 Adverse Reactions
6.1 Clinical Trials Experience(additions underlined)
…
Cholelithiasis and cholecystitis
In glycemic control trials of VICTOZA, the incidence of cholelithiasis was 0.3% in both VICTOZA- treated and placebo-treated patients. The incidence of cholecystitis was 0.2% in both VICTOZA-treated and placebo-treated patients.
In the LEADER trial, the incidence of cholelithiasis was 1.5% (3.9 cases per 1000 patient years of observation) in VICTOZA-treated and 1.1% (2.8 cases per 1000 patient years of observation) in placebo-treated patients, both on a background of standard of care. The incidence of acute cholecystitis was 1.1% (2.9 cases per 1000 patient years of observation) in VICTOZA-treated and 0.7% (1.9 cases per 1000 patient years of observation) in placebo-treated patients.
Laboratory Tests
…
Lipase and Amylase
In one glycemic control trial in renal impairment patients, a mean increase of 33% for lipase and 15% for amylase from baseline was observed for VICTOZA-treated patients while placebo-treated patients had a mean decrease in lipase of 3% and a mean increase in amylase of 1%.
In the LEADER trial, serum lipase and amylase were routinely measured. Among VICTOZA-treated patients, 7.9% had a lipase value at any time during treatment of greater than or equal to 3 times the upper limit of normal compared with 4.5% of placebo-treated patients, and 1% of VICTOZA-treated patients had an amylase value at any time during treatment of greater than or equal to 3 times the upper limit of normal versus 0.7% of placebo-treated patients.
The clinical significance of elevations in lipase or amylase with VICTOZA is unknown in the absence of other signs and symptoms of pancreatitis.
(additions underlined)
Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients treated with VICTOZA may develop anti-liraglutide antibodies. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, the incidence of antibodies to liraglutide cannot be directly compared with the incidence of antibodies of other products.
…
In the LEADER trial , anti-liraglutide antibodies were detected in 11 out of the 1247 (0.9%) VICTOZA-treated patients with antibody measurements.
Of the 11 VICTOZA-treated patients who developed anti-liraglutide antibodies, none were observed to develop neutralizing antibodies to liraglutide, and 5 patients (0.4%) developed cross-reacting antibodies against native GLP-1.
8 Use in Specific Populations
8.1 Pregnancy(PLLR conversion, please refer to label)
(PLLR conversion, additions underlined)
Risk Summary
There are no data on the presence of VICTOZA in human milk, the effects on the breastfed infant, or the effects on milk production. Liraglutide was present in milk of lactating rats [see Data].
Developmental and benefits of breastfeeding should be considered along with the mother’s clinical need for VICTOZA and any potential adverse effects on the breastfed infant from VICTOZA or from the underlying maternal condition.
Data
In lactating rats, liraglutide was present unchanged in milk at concentrations approximately 50% of maternal plasma concentrations.
(additions underlined)
In the VICTOZA treatment arms of the glycemic control trials, a total of 832 (19.3%) of the patients were 65 to 74 years of age and 145 (3.4%) were 75 years of age and over. No overall differences in safety or efficacy were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
In the VICTOZA treatment arm of the LEADER trial, a total of 1738 (37.2%) patients were 65 to 74 years of age, 401 (8.6%) were 75 to 84 years of age, and 17 (0.4%) were 85 years of age or older at baseline. No overall differences in safety or efficacy were observed between these patients and younger patients.
(additions underlined)
…
In the VICTOZA treatment arm of the LEADER trial, 1932 (41.4%) patients had mild renal impairment, 999 (21.4%) patients had moderate renal impairment and 117 (2.5%) patients had severe renal impairment at baseline. No overall differences in safety or efficacy were seen in these patients compared to patients with normal renal function.
….
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
PATIENT COUNSELING INFORMATION(additions underlined)
…
Acute Gallbladder Disease
Inform patients of the potential risk for cholelithiasis or cholecystitis. Instruct patients to contact their physician if cholelithiasis or cholecystitis is suspected for appropriate clinical follow-up.
04/25/2017 (SUPPL-28)
4 Contraindications
Subsection now broken into two subheadings with existing information:
Medullary Thyroid Carcinoma
Hypersensitivity
6 Adverse Reactions
6.1 Clinical Trials ExperienceAdditions and/or revisions underlined:
Common Adverse Reactions
The data in Table 1 are derived from 5 placebo-controlled clinical trials. These data reflect exposure of 1673 patients to VICTOZA and a mean duration of exposure to VICTOZA of 37.3 weeks. The mean age of patients was 58 years, 4% were 75 years or older and 54% were male. The population was 79% White, 6% Black or African American, 13% Asian; 4% were of Hispanic or Latino ethnicity. At baseline the population had diabetes for an average of 9.1 years and a mean HbA1c of 8.4%. Baseline estimated renal function was normal or mildly impaired in 88.1% and moderately impaired in 11.9% of the pooled population.
Table 1 shows common adverse reactions, excluding hypoglycemia, associated with the use of VICTOZA. These adverse reactions occurred more commonly on VICTOZA than on placebo and occurred in at least 5% of patients treated with VICTOZA.
Table 1 Adverse reactions reported in greater than or equal to 5% of VICTOZA-treated patients
Table data has changed; please refer to label.
Addition of the following:
*Cumulative proportions were calculated combining studies using Cochran-Mantel-Haenszel weights. In an analysis of placebo- and active-controlled trials, the types and frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed in Table 1.
Other Adverse Reactions
Gastrointestinal Adverse Reactions
In the pool of 5 placebo-controlled clinical trials, withdrawals due to gastrointestinal adverse reactions, occurred in 4.3% of VICTOZA-treated patients and 0.5% of placebo-treated patients. Withdrawal due to gastrointestinal adverse events mainly occurred during the first 2-3 months of the trials.
Additions and/or revisions underlined:
Injection site reactions
Injection site reactions (e.g., injection site rash, erythema) were reported in approximately 2% of
VICTOZA-treated patients in the five double-blind clinical trials of at least 26 weeks duration. Less than
0.2% of VICTOZA-treated patients discontinued due to injection site reactions.
Hypoglycemia
Hypoglycemia requiring the assistance of another person in placebo-controlled trials in 5 placebo-controlled clinical trials of at least 26 weeks duration, hypoglycemia requiring the assistance of another person for treatment occurred in 8 VICTOZA-treated patients (7.5 events per 1000 patient- years). Of these 8 VICTOZA-treated patients, 7 patients were concomitantly using a sulfonylurea.
Table 2 Incidence (%) and Rate (episodes/patient year) of Hypoglycemia in 26-Week Combination Therapy
Placebo-controlled Trials
Table title and data have changed; please refer to label.
“Patient not able to self-treat” is defined as an event requiring the assistance of another person for treatment
Malignancy
In a pooled analysis of clinical trials …beyond 1 year of exposure to study medication, six events among VICTOZA-treated patients (4 colon, 1 prostate and 1 nasopharyngeal), no events with placebo and one event with active comparator (colon). Causality has not been established.
Cholelithiasis and cholecystitis
In clinical trials of Saxenda (liraglutide at doses up to 3 mg), 1.5% and 0.6% of Saxenda-treated patients reported adverse events of cholelithiasis and cholecystitis versus 0.5% and 0.2% of placebo-treated patients. The majority of Saxenda-treated patients with adverse events of cholelithiasis and cholecystitis required cholecystectomy. In clinical trials of Victoza, the incidence of cholelithiasis was 0.3% in both Victoza-treated and placebo-treated patients. The incidence of cholecystitis was 0.2% in both Victoza treated and placebo-treated patients.
Laboratory Tests
Bilirubin
In the five clinical trials … (elevations to no more than twice the upper limit of the reference range) occurred in 4.0% of VICTOZA- treated patients, 2.1% of placebo-treated patients and 3.5% of active-comparator-treated patients …
Calcitonin
Calcitonin, a biological marker of MTC …active comparator. Between group differences … Among patients with pretreatment calcitonin less than 20 ng/L, calcitonin elevations to greater than 20 ng/L occurred in 0.7% of VICTOZA-treated patients, 0.3% of placebo-treated patients, and 0.5% of active-comparator-treated patients. The clinical significance of these findings is unknown.
Lipase and Amylase
In one placebo-controlled trial in renal impairment patients, a mean increase of 33% for lipase and 15%
for amylase from baseline was observed for VICTOZA-treated while placebo-treated patients had a mean decrease in lipase of 3% and a mean increase in amylase of 1%.The clinical significance of these changes is unknown.
Vital signs
VICTOZA did not have adverse effects on blood pressure. Mean increases from baseline in heart rate of 2 to 3 beats per minute have been observed …
Addition of the following:
Hepatobiliary disorders: elevations of liver enzymes, hyperbilirubinemia, cholestasis, hepatitis
8 Use in Specific Populations
Additions and/or revisions underlined:
8.6 Renal Impairment
No dose adjustment of VICTOZA is recommended for patients with renal impairment. The safety and efficacy of VICTOZA was evaluated in a 26-week clinical study that included patients with moderate renal impairment (eGFR 30 to 60 mL/min/1.73m2).There is limited experience with VICTOZA in patients with severe renal impairment including end stage renal disease ... Use caution in patients who experience dehydration.
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
PATIENT COUNSELING INFORMATIONAddition of the following:
Jaundice and Hepatitis
Inform patients that jaundice and hepatitis have been reported during postmarketing use of liraglutide. Instruct patients to contact their physician if they develop jaundice.
04/22/2016 (SUPPL-25)
6 Adverse Reactions
- Inclusion of results from Trial NN2211-3916, which was a 26-week double-blind placebo-controlled, randomized, multicenter, multinational, parallel-group trial which assessed the safety and efficacy of liraglutide in subjects with type 2 diabetes and moderate renal impairment.